Tenet Healthcare First Quarter 2025 Earnings: Beats Expectations

Simply Wall St

April 30, 2025

Tenet Healthcare (NYSE:THC) First Quarter 2025 Results

Key Financial Results

Revenue: US$5.28b (down 1.7% from 1Q 2024).
Net income: US$406.0m (down 81% from 1Q 2024).
Profit margin: 7.7% (down from 40% in 1Q 2024). The decrease in margin was primarily driven by higher expenses.
EPS: US$4.31 (down from US$21.60 in 1Q 2024).

Our free stock report includes 3 warning signs investors should be aware of before investing in Tenet Healthcare. Read for free now.

earnings-and-revenue-growth — NYSE:THC Earnings and Revenue Growth April 30th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tenet Healthcare Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 39%.

Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are up 21% from a week ago.

Valuation

It's possible that Tenet Healthcare could be undervalued with our 6-factor valuation analysis indicating a potential opportunity. Click here to find out what a fair price for the stock might be and where analysts see the share price heading over the next year.

Valuation is complex, but we're here to simplify it.

Discover if Tenet Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.